BioPharmSignal logoBioPharmSignal

Biotech News

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)

Jaguar Health (JAGX)Jaguar HealthCompany update

Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric and adult rare IF diseases, including microvillus inclusion disease (MVID)Company plans to file NDA for crofelemer for MVID in mid-2027 to

Related news

JAGXJaguar Health2026-07-22 13:00 EST

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)

JAGXJaguar Health2026-06-30 13:00 EST

Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)

IBRXImmunityBio2026-03-09 11:30 EST

ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data

SCYXSCYNEXIS2026-06-30 12:00 EST

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

HROWHarrow, Inc.2026-06-10 11:00 EST

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

IBRXImmunityBio2026-05-20 00:30 EST

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

SCYXSCYNEXIS2026-03-31 10:40 EST

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

HROWHarrow, Inc.2026-08-06 11:00 EST

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

ALZNAlzamend Neuro2025-05-29 12:00 EST

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

ALZNAlzamend Neuro2025-05-19 12:00 EST

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

View all latest news

Jaguar Health

Jaguar Health is a biopharmaceutical company focused on gastrointestinal and rare-disease therapies, with Mytesi as a key commercial asset. Its story combines niche commercialization with a pipeline aimed at high-unmet-need GI indications.

Recent company news

JAGXJaguar Health2026-09-15 13:00 EST

Jaguar Health, Inc. Announces Reverse Stock Split

JAGXJaguar Health2026-09-10 13:00 EST

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

JAGXJaguar Health2026-09-08 13:00 EST

Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs

JAGXJaguar Health2026-09-04 12:30 EST

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)

JAGXJaguar Health2026-08-26 13:00 EST

Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs

Stock data

Close
2.75 USD
Market cap
2.12M USD
Exchange
NASDAQ
Sector
Biopharma
Location
San Francisco, California